# A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

> **NCT05099159** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 400 (actual)

## Conditions studied

- Vasomotor Symptoms Associated With Menopause
- Hot Flashes

## Interventions

- **DRUG:** Elinzanetant (BAY3427080)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05099159
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2023-06-13
- **Final completion:** 2023-10-10
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05099159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05099159, "A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05099159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*